Skip to main content
Menu

AlphaLISA SureFire Ultra Mouse Total IRF9 Detection Kit, 500 Assay Points

The AlphaLISA™ SureFire® Ultra™ Mouse Total IRF9 assay is a sandwich immunoassay for quantitative detection of total IRF9 in cellular lysates using Alpha Technology.

Feature Specification
Application Cell Signaling
Protocol Time 2h at RT
Sample Volume 10 µL

The AlphaLISA™ SureFire® Ultra™ Mouse Total IRF9 assay is a sandwich immunoassay for quantitative detection of total IRF9 in cellular lysates using Alpha Technology.

Product variants
Unit Size: 100 assay points
Part #:
ALSU-TIRF9-B-HV
List price
USD 722.00
Your online price:
Unit Size: 500 assay points
Part #:
ALSU-TIRF9-B500
List price
USD 2,441.00
Your online price:
Unit Size: 10,000 assay points
Part #:
ALSU-TIRF9-B10K
List price
USD 14,688.00
Your online price:
Unit Size: 50,000 assay points
Part #:
ALSU-TIRF9-B50K
List price
USD 46,690.00
Your online price:
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Loading...

Overview

Interferon Regulatory Factor 9 (IRF9) is a transcription factor that forms the ISGF3 complex with STAT1 and STAT2 to mediate type I interferon signaling. Upon interferon-α/β receptor activation, JAK1 and TYK2 phosphorylate STAT1 and STAT2, which then associate with IRF9 to form the active ISGF3 complex. This complex translocates to the nucleus and binds interferon-stimulated response elements (ISREs) to induce expression of interferon-stimulated genes (ISGs) involved in antiviral defense, immune activation, and cell cycle regulation. IRF9 is essential for establishing an antiviral state and coordinating innate immune responses. Dysregulation of IRF9 is implicated in autoimmune diseases, viral persistence, and cancer immune evasion. Therapeutic modulation of IRF9 activity holds promise for enhancing antiviral immunity and cancer immunotherapy.

The AlphaLISA SureFire Ultra Mouse Total IRF9 is a sandwich immunoassay for the quantitative detection of total IRF9 in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • High-throughput screening for preclinical studies

How it works

Total-AlphaLISA SureFire Ultra assay principle

The Total-AlphaLISA SureFire Ultra assay measures the expression level of a protein target in a cell lysate.

The Total-AlphaLISA SureFire Ultra assay uses two antibodies which recognize two different distal epitopes on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of targeted protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.

assay-principle-Total-AlphaLISA-Surefire-Ultra.jpg

 

Total-AlphaLISA SureFire Ultra two-plate assay protocol

The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.

2 plates assay protocol AlphaLISA Surefire Ultra Total assay

Total-AlphaLISA SureFire Ultra one-plate assay protocol

Detection of Total target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.

1-plate-assay-protocol-AlphaLISA-Surefire-Ultra-Total-assay

Assay validation

IRF9 activation mediated by type I interferons

NIH/3T3 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. The cells were treated with 20 ng/mL of IFNα or IFNβ at the indicated timepoints.

After treatment, the cells were lysed with 200 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). IRF9 Total levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate (approximately 2,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, treatment with type I interferons triggered a significant increase in the levels of Total IRF9, with peak induction occurring at 8 hours with no change to Total Cofilin levels (data not shown).

NIH/3T3 cells treated with IFNα
NIH/3T3 cells treated with IFNβ

Type I and II interferons induce IRF9 in a dose-dependent manner

NIH/3T3 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of IFNα, IFNβ or IFNγ for 8 hours.

After treatment, the cells were lysed with 200 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). IRF9 Total and Cofilin Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 2,000 cells for IRF9 and 40 cells for Cofilin) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, treatment with type I and type II interferons triggered a dose-dependent increase in the levels of Total IRF9 with no change to Cofilin levels.

IRF9 activation mediated by type I interferons
IRF9 activation mediated by type I interferons
IRF9 activation mediated by type I interferons

 

Decrease of IRF9 mediated by JAK inhibitors

RAW 264.7 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of Ruxolitinib for 8 hours.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Total IRF9 and Cofilin levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells for IRF9 and 400 cells for Cofilin) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Inhibition of JAK1 signaling, mediated by Ruxolitinib induced a significant decrease of Total IRF9 levels after 8 hours, while Cofilin Total levels remained unchanged.

Decrease of IRF9 Total mediated by JAK inhibitors

RAW 264.7 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were treated 5 µM of Pacritinib for 8 hours.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Total IRF9 and Cofilin levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells for IRF9 and 400 cells for Cofilin) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Inhibition of JAK1 signaling, mediated by Pacritinib, induced a significant decrease of Total IRF9 levels after 8 hours, while Cofilin Total levels remained unchanged (data not shown).

Decrease of IRF9 Total mediated by JAK inhibitors

Assay versatility

Total IRF9 expression in mouse cell lines

Adherent cell lines were seeded in a 96-well plate (40,000 cells/well) and incubated overnight at 37°C, 5% CO2. Cells were lysed with 100 µL of Lysis Buffer at RT with shaking (350 rpm).

IRF9 levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, basal Total IRF9 expression is low in most mouse cell lines tested. High levels of expression were detected in MEF cells and moderate expression in RAW 264.7 cells.

Total IRF9 expression in mouse cell lines

Specifications

Application
Cell Signaling
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Product Group
Kit
Protocol Time
2h at RT
Sample Volume
10 µL
Shipping Conditions
Shipped in Blue Ice
Target
IRF9
Target Class
Phosphoproteins
Target Species
Mouse
Technology
Alpha
Therapeutic Area
Inflammation
Oncology
Virology
Unit Size
500 assay points

Resources

Are you looking for resources, click on the resource type to explore further.

1-3 of 3 Resources
Brochure Icon
Brochure
Alpha assays and reagents catalog

Alpha technolgy enables the rapid and straightforward mesaure of virtually any target. This includes enzymes, receptor-ligand...

Brochure Icon
Brochure
Alpha SureFire Ultra no-wash immunoassay catalog

Discover Alpha SureFire® Ultra™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology...

Brochure Icon
Brochure
Species compatibility for HTRF, AlphaLISA SureFire Ultra and Alpha SureFire Ultra Multiplex assays

This document includes detailed tables listing HTRF™, AlphaLISA™ SureFire® Ultra™, and Alpha SureFire® Ultra™ Multiplex assays...

Scroll Icon

Revvity AI Assistant Beta